Loading clinical trials...
Loading clinical trials...
Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors
Conditions
Interventions
BMS-986466
Adagrasib
+1 more
Locations
9
United States
Local Institution - 0047
Los Angeles, California, United States
Local Institution - 0040
Athens, Georgia, United States
Local Institution - 0025
Hackensack, New Jersey, United States
Local Institution - 0008
Morristown, New Jersey, United States
Local Institution - 0053
Westmead, New South Wales, Australia
Local Institution - 0083
Helsinki, Finland
Start Date
November 9, 2023
Primary Completion Date
May 13, 2024
Completion Date
May 13, 2024
Last Updated
July 22, 2025
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions